Physiomics (PYC) RNS Announcements

Add to Alert list
Date Time Source Announcement
17 Dec 2007 07:00 AM
RNS
MOU with Swansea University
12 Dec 2007 11:08 AM
RNS
Collaboration Update
30 Nov 2007 01:54 PM
RNS
Holding(s) in Company
28 Nov 2007 07:00 AM
RNS
Final Results - Replacement
27 Nov 2007 10:33 AM
RNS
Final Results
24 Sep 2007 03:59 PM
RNS
Holding(s) in Company
17 Sep 2007 05:25 PM
RNS
Holding(s) in Company
17 Sep 2007 11:38 AM
RNS
Holding(s) in Company
17 Sep 2007 09:00 AM
RNS
Collaboration with Eli Lilly
16 Aug 2007 07:01 AM
RNS
AIM rule 26 information
13 Aug 2007 02:35 PM
RNS
Holding(s) in Company
07 Aug 2007 04:28 PM
RNS
Holding(s) in Company
18 May 2007 03:53 PM
RNS
Directorate Change
16 Mar 2007 11:15 AM
RNS
Interim Results
02 Jan 2007 07:00 AM
RNS
Result of AGM
19 Dec 2006 01:01 PM
RNS
Total Voting Rights
07 Dec 2006 02:54 PM
RNS
Notice of AGM and prelims
28 Nov 2006 07:01 AM
RNS
TEMPO project participation
07 Nov 2006 04:47 PM
RNS
Holding(s) in Company
29 Sep 2006 02:46 PM
RNS
Additional Listing
28 Sep 2006 12:49 PM
PRN
EGM Statement
05 Sep 2006 02:41 PM
PRN
Notice of EGM
01 Sep 2006 03:25 PM
PRN
Board Changes, Placing and Change of Broker
08 Jun 2006 10:03 AM
PRN
Directorate Change
28 Apr 2006 07:00 AM
PRN
Holding(s) in Company
31 Mar 2006 07:00 AM
PRN
Interim Results
22 Dec 2005 01:04 PM
PRN
AGM Statement
25 Oct 2005 04:02 PM
PRN
Statement re: Partial Investing of Share Options
18 Oct 2005 01:06 PM
PRN
Director/PDMR Shareholding
08 Sep 2005 07:00 AM
PRN
Final Results
26 Aug 2005 07:00 AM
PRN
Directorate Change
28 Jun 2005 11:48 AM
PRN
Additional Listing
27 Jun 2005 07:00 AM
PRN
Statement re share subscription and issue of op...
23 Jun 2005 07:00 AM
PRN
Re Agreement
21 Mar 2005 07:00 AM
PRN
Interim Results
23 Dec 2004 04:54 PM
PRN
Registration of UK SystemCell(TM) Patent
20 Dec 2004 07:00 AM
PRN
FIRST DAY OF TRADING ON AIM

Physiomics plc is a UK-based company that uses mathematical models to help develop cancer treatments and personalized medicine. Services include Virtual Tumor modeling: A combination of proprietary and industry standard technologies that predict the effects of cancer treatments and drugs, Answering R&D questions: Helping clients de-risk drug development and build confidence in a molecule's clinical potential and Predicting therapeutic windows: Helping clients achieve a more quantitative understanding of new molecules.

PYC share price listed at 231p in 2004.

UK 100

Latest directors dealings